Bioxytran, Inc (BIXT) stock
BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.02−0.00 (-3.95%)
Close on Oct 19, 2026Market cap $2.56MP/E –Yield –
Bioxytran gross margin
Gross margin is gross profit as a percentage of revenue.
Bioxytran's gross margin for the twelve months ending Jun 30, 2018 was 47.1%. For fiscal 2017 it was 45.6%, against 60.9% the year before. The highest annual figure on record is 75.0% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | 45.6% | −15.3 |
| FY2016 | Dec 31, 2016 | 60.9% | +14.0 |
| FY2015 | Dec 31, 2015 | 47.0% | +7.2 |
| FY2014 | Dec 31, 2014 | 39.8% | −12.9 |
| FY2013 | Dec 31, 2013 | 52.7% | −8.3 |
| FY2012 | Dec 31, 2012 | 61.0% | −14.0 |
| FY2011 | Dec 31, 2011 | 75.0% | +0.0 |
| FY2010 | Dec 31, 2010 | 75.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | 60.0% | +9.2 |
| Q1 FY2018 | Mar 31, 2018 | -14.5% | +69.4 |
| Q4 FY2017 | Dec 31, 2017 | -20.5% | −81.9 |
| Q3 FY2017 | Sep 30, 2017 | 71.5% | +9.3 |
| Q2 FY2017 | Jun 30, 2017 | 50.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -83.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 61.4% | – |
| Q3 FY2016 | Sep 30, 2016 | 62.2% | – |
See a number that looks wrong?